Objective: The risk of clinically significant depressive symptoms increases during perimenopause. With highly active antiretroviral treatment (HAART), more human immunodeficiency virus (HIV)Yinfected women survive to transition through menopause. In a cross-sectional analysis, we evaluated the association of menopausal stage and vasomotor symptoms with depressive symptoms in an ethnically diverse cohort of women with a high prevalence of HIV.
A lthough mood complaints at midlife have long been attributed to menopause, there has been substantial debate regarding the impact of menopause on mood and cognition. 1 The 2005 National Institutes of Health Stateof-the-Science Conference Statement on Management of Menopause-Related Symptoms concluded that there is strong evidence from both longitudinal and cross-sectional observational studies that the menopausal transition causes vasomotor symptoms and vaginal dryness. 1 In contrast, evidence indicating that the menopausal transition leads to mood changes was considered Bmixed.[ Although large gaps in knowledge remain, a number of recent studies have informed our understanding of mood symptoms at midlife. The scientific literature indicates that most women experience the menopausal transition without mood difficulties. However, there are six studies that characterize the perimenopausal stage as a period of increased risk for elevated depressive symptoms and/or depressive disorders, including a study of women from Eindhoven, Netherlands 2 ; the Study of Women's Health Across the Nation (SWAN) 3<6 ; the National Institutes of Mental Health 7 ; the Penn Ovarian Aging (POA) study 8, 9 ; the Harvard Study of Moods and Cycles 10 ; and the Seattle Midlife Women's Health Study. 11 The magnitude of this risk is sizeable, with studies using diagnostic clinical interviews finding a twofold to fourfold increased risk of depression during the transition in women with no previous history of mood disorder. 5, 7, 10 One limitation of our understanding of perimenopauserelated depression is that research on this topic has largely been confined to cohorts of healthy women of middle-class or higher socioeconomic status. Two exceptions are the ethnically diverse cohort of women studied in the SWAN, a sample that included 28% African American women and 8% Latina, 3 and the POA study, a sample that included 50% African American women. 8, 9 One significant and as yet unstudied question concerning perimenopausal depression is whether women of lower socioeconomic status may be at increased risk for perimenopausal depression because of other exacerbating factors, including low income, low educational attainment, unemployment, interpersonal violence, and drug and alcohol use. 12 Similarly, because previous studies were based on cohorts of healthy women, little is known about the differential risk of depression among healthy women versus those with serious medical illnesses. Understanding the factors that are associated with depression in human immunodeficiency virus (HIV)Yinfected women is especially important because depression is associated with nonadherence to highly active antiretroviral treatment (HAART) and increased mortality. 13, 14 We therefore investigated the potential interactive effects of menopausal stage and HIV status on elevated depressive symptoms in the Women's Interagency HIV Study (WIHS). The WIHS is the largest study of the natural and treated history of HIV in women. Here, we report data from 835 HIV-infected women and 335 HIV-uninfected controls. One substantial benefit of examining this question in the WIHS is that the controls are similar to the HIV-infected women in risk factors for depressive symptoms and HIV. We hypothesized that there would be an increased risk for elevated depressive symptoms in the perimenopausal period and that this risk would be higher in HIV-infected women. We further hypothesized that women treated with HAART would show lower depressive symptoms in the perimenopausal period compared with women who have not received HAART because of evidence that initiation or maintenance of HAART decreases depressive symptoms in women with HIV. 15, 16 
METHODS

Study population
The WIHS is a longitudinal, multicenter study of the natural and treated history of HIV infection in women and includes six clinical sites, including Bronx/Manhattan, NY; Brooklyn, NY; Chicago, IL; Washington, DC; San Francisco, CA; and Los Angeles, CA. 17, 18 Study methodology, training, and quality assurance procedures, as well as the cohort's baseline characteristics, have been reported previously. 17, 18 In brief, there were two waves of enrollment in the WIHSV the first in October 1994 and the second in [2001] [2002] (N = 3,766). At each enrollment, HIV-infected and HIVuninfected women were similar in age, race/ethnicity, level of education, recruitment site, and risk factors, including history of use of injection drug and number of sexual partners. 17, 18 Eligibility criteria at enrollment into the WIHS included the following: 13 years or older, provision of informed consent form, and ability to complete an interview in either English or Spanish. WIHS participants complete Bcore[ visits every 6 months; at each of these visits, they undergo clinical examination, extensive medical interview, filling out of questionnaires (including the Center for Epidemiologic Studies Depression Scale [CES-D]), and blood draw. This analysis was restricted to data collected as part of a cross-sectional study of menopause, cognition, and mood that was incorporated into WIHS core visits in April 2007 to April 2008. A total of 1,901 WIHS participants were assessed during that time frame, and 1,458 of those women met the entry criteria as follows: (1) age 30 to 65 years (n = 203 excluded), (2) completion of the CES-D (n = 21 excluded), and (3) completion of detailed questions about menstrual cycle characteristics used to determine menopause status (n = 219). Of the 1,458 participants, we included 1,170 (80% of the cohort) after excluding participants meeting one or more of the following exclusion criteria: (1) currently pregnant or breast-feeding (n = 9) and (2) underwent hysterectomy or bilateral oophorectomy (n = 180) and/or used hormone therapy or oral contraceptives within the past 6 months (n = 124). In BResults,[ we compare the characteristics of women who were included in this analysis (n = 1,170; 80% of overall sample) and those who were excluded (n = 731).
Measures
Primary outcome
Depressive symptoms. The primary outcome was clinically indicated depression as assessed by the CES-D, 19 a 20-item self-report measure of depressive symptoms. The CES-D has excellent reliability, validity, and factor structure 19 and is commonly used in studies of HIV-infected cohorts, 20 including studies of HIV-infected women. 21 The instrument has been studied extensively in the WIHS, including studies of perinatal depression. 22 Importantly, a validation study in the WIHS demonstrated that the standard cutoff of 16 produced virtually identical associations with the use of antiretroviral therapy and the woman's demographic characteristics when compared with alternative cutoffs, including a more stringent cutoff of 23, and an interval-level version of the subscale that excluded somatic items similar to HIV symptoms. 13 Thus, this study used the standard cutoff score of 16. The CES-D sensitivity for the diagnosis of major depression is excellent, in the range of 80% to 90%, with a somewhat lower specificity, in the range of 70% to 80%. 12, 16, 23 Menopausal stage classification. Menopausal stage was explicitly assessed in the medical interview and classified according to definitions used in the SWAN. This allowed us to compare our findings with those from the SWAN, which is the largest study of the menopausal transition in the United States and has produced a series of important findings regarding depression and the menopausal transition.
3<6 Importantly, the SWAN criteria are very similar to criteria set forth in the Stages of Reproductive Aging Workshop consensus statement. 24 The definitions were as follows: premenopausal, menses in the past 3 months with no changes in regularity; early perimenopausal, menses in the past 3 months with changes in regularity; late perimenopausal, no menses within the past 3 months but some menstrual bleeding within the past 12 months; and postmenopausal, no menses within the past 12 months.
Covariates. The primary factors of interest were menopausal stage, HIV serostatus, and the interaction of the two variables. In addition to age, race/ethnicity, level of education (less than high school education vs greater than high school education), and site (Bronx; Brooklyn; Washington, DC; Los Angeles; San Francisco; and Chicago), a number of potential covariates and predictors of risk factors for elevated depressive symptoms were examined based on previous literature in the WIHS and other studies. 12 Sociodemographic covariates included marital status (married vs living with a partner vs all other participants), employment status, average household income (e$12,000 vs 9$12,000), and insurance status. Other covariates included current smoking status; recent alcohol use (abstainer vs moderate drinker [e7 drinks/wk] vs heavy drinker [97 drinks/wk]); past heavy alcohol use during the WIHS (97 drinks/wk); recent use (last 6 mo) of marijuana/ hash; use of crack, cocaine, and/or heroin via any means of administration (never, past, and current); and current number of sexual partners (G2 vs Q2). We also included medical factors: self-reported use of antidepressant medication (never, past, and current), previous CES-D score higher than 16 during the WIHS, and hepatitis C virus antibody. We also examined covariates related to reproductive health, including past use of menopausal hormone therapy, parity, and body mass index, as well as vasomotor symptoms. Vasomotor symptoms were ascertained using a questionnaire from the SWAN and were categorized as high when women reported experiencing more than half of the individual vasomotor items (hot flashes or night sweats) on 6 days or more in the past 2 weeks. 3 In analyses restricted to HIV-infected women, we also assessed HAART use (no HAART vs HAART and G95% compliant with prescribed dosing vs HAART and Q95% compliant), duration of HAART (years), CD4 count (a measure of immunologic function in HIV infection), and viral load (number of copies of HIV RNA per milliliter of plasma, which is an indicator of the rate of viral replication at the current time).
Statistical analyses
Differences in demographic characteristics between HIVinfected and HIV-uninfected women were examined using independent t tests for continuous variables and W 2 tests for categorical variables. Next, W 2 tests were computed to examine the prevalence of elevated depressive symptoms (CES-D score Q16) as a function of menopausal stage, HIV serostatus (infected vs uninfected), and menopausal stage Â serostatus. Subsequently, unadjusted logistic regression models were used to assess the association of serostatus, menopausal stage, and other potential risk factors (eg, risky health behaviors, sociodemographic factors, and reproductive health factors, as described above) with elevated depressive symptoms. Odds ratios (ORs) and 95% CIs were calculated using maximum likelihood estimates from the logistic regression models. Based on simple regression techniques, predictors found to be significant were examined in subsequent multivariable logistic regression analyses examining the impact of menopausal stage, serostatus, and their interaction on elevated depressive symptoms. Age, race/ethnicity, site, and education were included in all analyses. Forward and backward selection procedures (performed manually) were used to determine the best-fitting model, with menopausal stage and serostatus forced in the models. All P values are two sided, and the statistical significance level was set at P G 0.05. All analyses were performed using SAS, version 9.2 (SAS Institute, Inc., Cary, NC). Table 1 shows demographic and clinical information for the 835 HIV-infected women, the 335 HIV-uninfected women, and the combined sample of 1,170 women. Participants ranged in age from 30 to 65 years (mean [SD], 44.19 [7. 42] years). Minority representation was high, with 63% African American and 20% Latina participants. The average income was low, with 51% of the sample having annual incomes below $12,000. Lifetime use of illicit substances (ie, crack, cocaine, and/or heroin) was common (64%). Only 13% reported use of illicit substances since the previous study visit 6 months earlier, with more HIV-uninfected (16%) than HIV-infected (12%) women reporting current use (P G 0.05). Rates of recent use of marijuana, cigarettes, and alcohol were also higher among uninfected versus infected women (P G 0.001). Among HIV-infected women, 16% had a current CD4 + lymphocyte count of fewer than 200 cells/KL. Plasma HIV RNA was not detected (lower limit of detection was 80 copies/mL) in 50%, indicating optimal treatment response. Viral load was greater than the lower limit of quantitation but less than 10,000 copies/mL for 32% of HIV-infected women and greater than 10,000 copies/mL for 18% of HIV-infected women. Sixty-three percent had been prescribed HAART therapy, and 75% reported adherence to greater than 95% of prescribed doses.
RESULTS
Population characteristics
Compared with the 731 women excluded from this analysis (see ''Study Population''), the 1,170 women included in the analysis were more likely to be older (44.2 vs 41.0 years, P G 0.001); to be black non-Hispanic (63% vs 49%, P G 0.001); to have at least a high school education (65% vs 56%, P G 0.001); to be living alone (72% vs 64%, P = 0.001); to smoke (49% vs 34%, P G 0.001); to have engaged in hazardous drinking in the past (36% vs 27%, P G 0.001); to have used crack, cocaine, and/or heroin recently or in the past (65% vs 42%); to have recently used marijuana (19% vs 14%, P = 0.02); and to have more depressive symptoms (38% vs 32%, P = 0.01).
Prevalence of depressive symptoms
In unadjusted analyses, 38% of the women had CES-D scores of 16 or higher. The prevalences of elevated depressive symptoms among HIV-infected and HIV-uninfected women were the same, at 38% each. Notably, the prevalences of elevated depressive symptoms differed by menopausal stage: 33% among premenopausal women, 47% among early perimenopausal women, 42% among late perimenopausal women, and 43% among postmenopausal women (W 2 1 = 15.95, P G 0.001, n = 1,170). Within these four strata, the prevalences of elevated depressive symptoms for HIV-infected and HIVuninfected women were similar (P 9 0.18). Table 2 shows the results from the unadjusted and adjusted regression analyses. Variables found to be significant in the unadjusted analyses included unemployment; low social support; low household income; higher number of current sexual partners; current smoking; past and recent heavy use of alcohol; past and recent illicit use of crack, cocaine, and/or heroin; hepatitis C virus infection; recent use of antidepressants; and persistent vasomotor symptoms. In the total population, early perimenopausal stage was associated with a greater likelihood of elevated depressive symptoms, both in unadjusted (OR, 1.77; 95% CI, 1.26-2.48; P = 0.001) and adjusted (OR, 1.74; 95% CI, 1.17-2.60; P = 0.007; Fig. 1 ) analyses. Similarly, in analyses restricted to HIV-infected women, those in the early perimenopausal stage had significantly higher depressive symptom severity than did those in the premenopausal stage, both in unadjusted (OR, 1.97; 95% CI, 1.29-2.99; P = 0.002) and adjusted (OR, 1.92; 95% CI, 1.16-3.19; P = 0.01) analyses. Contrary to our hypotheses, there was no interaction between HIV infection status and menopausal stage, indicating that HIV-infected women were not more likely to report elevated depressive symptoms in the early perimenopausal stage when compared with HIV-uninfected women. Among HIV-infected women, a CD4 count of fewer than 200 cells/KL was also associated with a higher rate of depression (OR, 2.14; 95% CI, 1.29-3.56; P e 0.003), and HAART adherence was associated with a lower rate of depression (OR, 0.67; 95% CI, 0.46-0.96; P = 0.03).
To examine the influence of HAART on perimenopausal depression, a final exploratory multivariable regression was conducted in HIV-infected women only. Medication use (no HAART, HAART and G95% compliant, and HAART and Q95% compliant), menopausal stage, and their interaction were forced in the model, along with relevant covariates from the analysis of the larger sample. There was a significant interaction between menopausal stage (ie, early perimenopausal vs premenopausal) and HAART use (P = 0.02). Specifically, among HIV-infected women who reported not taking HAART, those in the early perimenopausal stage were more than 3.9 times as likely to report elevated depressive symptoms as those in the premenopausal stage (OR, 3.87; 95% CI, 1.57-9.55; P = 0.003).
DISCUSSION
The aim of this investigation was to examine the likelihood of elevated depressive symptoms in relation to menopausal stage in an ethnically diverse cohort of low-income HIVinfected and HIV-uninfected women. The finding that depressive symptoms are elevated during the perimenopausal stage in healthy cohorts has been established in a number of studies. 2<11 The present study demonstrates that the link between perimenopausal stage and elevated depressive symptoms extends to women with a high prevalence of poverty (ie, 51% had household incomes below the established poverty line) and ethnic diversity (ie, 66% African American and 20% Latina). Notably, most women in this study were HIV-infected (ie, 69%), but HIV-infected women were not more likely than HIV-uninfected women to show elevated depressive symptoms during the perimenopausal stage. Overall, the likelihood of elevated depressive symptoms was 74% higher in the early perimenopausal stage compared with the premenopausal stage, after controlling for significant covariates. Elevated risk was also evident in analyses restricted to HIV-infected women. Women with persistent vasomotor symptoms were 45% more likely to show elevated depressive symptoms. Other factors associated with depressive symptoms in this cohort have been reported in previous studies and include a history of probable depression, unemployment, low income, higher number of sexual partners, and current and past use of antidepressant medication. 5, 9 In HIV-infected women, adherence to HAART was protective, and CD4 lymphocyte counts of fewer than 200 cells/mL (indicating more advanced HIV immune injury) were associated with elevated depressive symptoms.
It is useful to compare findings from the present study with those from the SWAN and the POA study. Like the present study, the SWAN and the POA study used similar definitions of menopausal stage and elevated depressive symptoms (ie, CES-D 916) and drew on ethnically diverse (albeit healthier and more economically advantaged) cohorts. Importantly, although all three studies used premenopausal stage as a reference for risk in later reproductive stages, the SWAN and the POA study assessed risk longitudinally, 4,9 allowing within-person estimates of risk. In contrast, WIHS estimates are based on a cross-sectional design. The likelihood of elevated depressive symptoms in the early perimenopausal stage versus the premenopausal stage was significant in all three studies: 74% higher in the WIHS, 30% higher in the SWAN, 4 and 55% higher in the POA study. 9 Given our study's low representation of women in the late perimenopausal stage (only 57 of 1,170 participants), it may be that our analysis was underpowered to detect differences for the late perimenopausal stage that were observed in both the SWAN and POA study. The risk in the postmenopausal period was not significant in the present study, was 57% higher in the SWAN, and was not significant in the POA study, which was underpowered to detect that particular effect. Ongoing data collection in the WIHS will allow for comparisons with the SWAN and the POA study based on a longitudinal design.
It is notable that an association between menopausal stage and depressive symptom severity is observed despite the high prevalence of unemployment, poverty, and other risk factors that contribute to depressive symptoms in this cohort. In our cohort, 58% of women were unemployed, and unemployment was associated with a 2.3-fold increased likelihood of elevated depressive symptoms. In the SWAN, 8% of the cohort reported that paying for basics was Bvery[ hard, and the likelihood of elevated depressive symptoms was two times higher among those women. 4 In the POA study, 18% of participants were unemployed, and unemployment was associated with a 97% increased likelihood of elevated depressive symptoms.
Although HIV-infected women showed significantly higher depressive symptom severity during the early perimenopausal period than during the premenopausal period, the magnitude of severity was not significantly different from that observed among the HIV-uninfected women. Similarly, we recently reported that HIV-infected women were more at risk for depression during the perinatal period than during the antenatal period, but their risk was not higher than that of controls. 22 Together, these two findings suggest that HIV-infected WIHS participants were not more likely than HIV-uninfected participants to show elevated depressive symptoms during reproductive transitions. It remains to be seen whether these results generalize to other cohorts of HIV-infected women, including those who do not receive HAART and who are not involved in studies that can provide social support and improved medical monitoring. Contrary to other HIV-infected women, HIV-infected women who were adherent to HAART did not show an elevated risk of depression during the perimenopausal period. On the basis of that finding, we might expect to find higher rates of perimenopausal depression among cohorts of HIV-infected women who are less adherent to HAART. As noted earlier, elevated depressive symptoms are linked to nonadherence to HAART and greater mortality. 13, 14 The factors contributing to higher depressive symptom severity in the perimenopausal period compared with the premenopausal period are unclear. Consistent with other investigations, we found that moderate to severe vasomotor symptoms were associated with increased odds for elevated depressive symptoms. 4, 5, 11 Risk for depression has been associated with high levels of follicle-stimulating hormone and luteinizing hormone, as well as increased variability in estradiol, folliclestimulating hormone, and luteinizing hormone, as measured over two consecutive months, 8, 9 although other studies found no association between annual hormone measurements and risk of depression. 5 Other studies reported an association between a history of postpartum depression and increased risk of depression in the perimenopausal stage. 9, 25 Our results suggest that HIV care providers should be alert to the possibility of increased depressive symptoms in FIG. 1 . Association of menopausal stage with depressive symptoms. *P G 0.05. Referent for early peri, late peri, and post was premenopausal. ''Recent Use'' refers to use in the past 6 months (since last WIHS visit). Depressive symptoms were elevated in the early perimenopause compared to premenopause. Unemployment, having two or more sexual partners, current smoking, recent use of antidepressants, and persistent vasomotor symptoms were related to increased odds of depressive symptoms. Findings are adjusted for age, race/ethnicity, site and education. HIV, human immunodeficiency virus; Peri, perimenopause; Post, postmenopause.
HIV-infected women who report a new onset of menstrual cycle irregularity. Longitudinal analyses of depressive symptoms and adherence in WIHS participants demonstrate an association between depressive symptoms and nonadherence to HAART. 13 In that light, treatment of perimenopausal depressive symptoms may enhance adherence to antiretroviral therapy and thereby improve health outcomes in HIV-infected women. Related to this is our exploratory cross-sectional finding that women in the present study who are not taking HAART showed a 3.9-fold increased odds of elevated depressive symptoms during early perimenopause. Longitudinal follow-up of these women is ongoing and will provide important information about patterns of depression and HAART use over time. Information about the efficacy of hormonal and nonhormonal interventions in the treatment of mood disorders in the perimenopausal and postmenopausal stages comes from clinical trials in healthy women, but these therapies have not been tested in HIV-infected women with perimenopausal depression. For example, transdermal estrogen therapy, escitalopram, and desvenlafaxine have been shown to be effective therapies for perimenopausal mood disorders in HIV-uninfected women.
26<28 Both selective serotonin reuptake inhibitors are used in treating depression in individuals with HIV, and a recent review provides useful information about diagnosing and treating depression in women with HIV. 29 Use of estrogen therapies requires further investigation because HIV infection is associated with an increased risk of thrombotic events. 30, 31 There were several limitations to the study. Primary among these is the cross-sectional design. Second, elevated depressive symptoms were measured using the CES-D rather than diagnostic interview. Third, compared with WIHS participants who were excluded from this study (eg, based on age, pregnancy, and hormone use), those included in this study showed higher depressive symptoms and more risk factors for depressive symptoms (eg, past drug use); thus, the generalizability of these findings remains to be determined. We do not have information on important mental health variables that might alter the findings, including history of depression diagnosis, indications for antidepressant use (women with HIV are prescribed antidepressants for neuropathy, among other reasons), and years of HIV infection. Longitudinal studies are underway in the WIHS to evaluate the risk of elevated depressive symptoms and clinical depression based on diagnostic interview as women transition through menopause and to further assess the impact of vasomotor symptoms and HAART adherence on perimenopausal depression.
CONCLUSIONS
Our results extend previous studies of perimenopausal depression in healthy, highYsocioeconomic status cohorts to a large sample of women with HIV. Our finding that depressive symptoms were most evident in women who were nonadherent to HAART supports a need to further understand the relationship between medication adherence and symptoms of depression in perimenopausal women with HIV.
